Logo of Clinuvel Pharmaceuticals (ASX:CUV)Latest Clinuvel Pharmaceuticals (ASX:CUV) News

Page 1
Page 1 of 3

Clinuvel maps A$220 million transformation as CUV107 slips to February

Clinuvel has outlined a multi-year expansion from peptide therapeutics into polymers, long-acting injectables, devices and digital health, backed by A$220 million of planned FY2027-FY2030 spending. The strategy comes with a near-term setback: first patient treatment in the CUV107 vitiligo study has been delayed to February 2027.
Victor Sage
6 Nov 2026

Clinuvel files European dossier for second pharmaceutical product

Clinuvel has submitted NEURACTHEL Instant for regulatory review in three initial European Union markets, opening a potential pathway for its second pharmaceutical product. The decentralised review is expected to take 300 days, excluding clock stops, but the product is not yet approved anywhere.
Victor Sage
30 Oct 2026

Healthcare Wrap - Week 35 (24 Aug -> 28 Aug) 2026

Healthcare shares split sharply this week, with Biome Australia rising while Nanosonics, Epiminder and Saluda Medical fell heavily.
Profits, trial progress and new approvals competed with cash needs, debt concerns and weaker investor confidence.
Logan Eniac
29 Aug 2026

Clinuvel Reports Tenth Profit, Plans Nasdaq Listing and U.S. HQ Move

Clinuvel Pharmaceuticals marked its tenth consecutive profit with stable revenues and rising cash reserves, while accelerating U.S. expansion including a Nasdaq uplisting and potential ASX delisting.
Victor Sage
27 Aug 2026

Healthcare Wrap - Week 31 (27 July -> 31 July) 2026

Xenitra led the healthcare board after a three-year Chinese pharmaceutical deal, while Artrya and InteliCare delivered the week’s biggest contrasting moves. Across the sector, companies raised cash, won regulatory support and pushed deeper into US hospitals and clinics.
Logan Eniac
1 Aug 2026

Clinuvel Sets December 2026 for Vitiligo Trial Results, Phase III to Start November

Clinuvel Pharmaceuticals targets year-end for topline results from its pivotal vitiligo trial of SCENESSE® combined with narrowband UVB, aiming to expand the drug's use beyond its current rare disease indication.
Ada Torres
28 July 2026

Market Wrap - Week 30 (20 July -> 24 July) 2026

Takeovers, mine studies and record quarterly updates drove the week, with buyers chasing companies that put hard numbers around cash flow, reserves and contract wins. Losses were just as sharp where traders sold into reopenings or questioned whether fresh capital and non-binding deals would turn into profits.
Logan Eniac
25 July 2026

Healthcare Wrap - Week 30 (20 July -> 24 July) 2026

Lumos led healthcare stocks higher after widening its US urgent care rollout, while Tissue Repair tumbled on its plan to leave the ASX. Strong trial updates, FDA steps and fresh funding kept the sector busy, even as several stocks fell despite good news.
Logan Eniac
25 July 2026

CLINUVEL Shifts Headquarters to US and Cuts Workforce to Target US Market

CLINUVEL Pharmaceuticals is relocating its corporate headquarters to the United States and reducing its global workforce by up to 20%, realigning its operations to focus solely on the US pharmaceutical market and unlock greater capital access.
Ada Torres
23 July 2026

Market Wrap - Week 29 (13 July -> 17 July) 2026

Wild swings hit the ASX this week, with Janus Electric doubling, Aura sliding almost 30%, and TechGen jumping more than 22%. Big news kept landing, but many stocks still fell as early gains faded and traders locked in profits.
Logan Eniac
18 July 2026

Healthcare Wrap - Week 29 (13 July -> 17 July) 2026

Big price swings hit healthcare stocks this week, but the sharpest falls did not always match the news flow. Revenue growth, trial progress and fresh US deals kept buying interest alive across parts of the sector.
Logan Eniac
18 July 2026

Health Canada Grants Approval for CLINUVEL’s SCENESSE to Treat Rare EPP Disorder

CLINUVEL Pharmaceuticals secures Canadian marketing approval for SCENESSE®, expanding access to the only approved systemic photoprotective treatment for erythropoietic protoporphyria (EPP).
Victor Sage
13 July 2026